GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gan & Lee Pharmaceuticals Co Ltd (SHSE:603087) » Definitions » EV-to-Revenue

Gan & Lee Pharmaceuticals Co (SHSE:603087) EV-to-Revenue : 9.27 (As of Jun. 03, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Gan & Lee Pharmaceuticals Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Gan & Lee Pharmaceuticals Co's enterprise value is ¥32,162 Mil. Gan & Lee Pharmaceuticals Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ¥3,470 Mil. Therefore, Gan & Lee Pharmaceuticals Co's EV-to-Revenue for today is 9.27.

The historical rank and industry rank for Gan & Lee Pharmaceuticals Co's EV-to-Revenue or its related term are showing as below:

SHSE:603087' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.68   Med: 9.1   Max: 34.52
Current: 9.27

During the past 12 years, the highest EV-to-Revenue of Gan & Lee Pharmaceuticals Co was 34.52. The lowest was 4.68. And the median was 9.10.

SHSE:603087's EV-to-Revenue is ranked worse than
80.58% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: 3.09 vs SHSE:603087: 9.27

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-03), Gan & Lee Pharmaceuticals Co's stock price is ¥57.16. Gan & Lee Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ¥5.89. Therefore, Gan & Lee Pharmaceuticals Co's PS Ratio for today is 9.70.


Gan & Lee Pharmaceuticals Co EV-to-Revenue Historical Data

The historical data trend for Gan & Lee Pharmaceuticals Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gan & Lee Pharmaceuticals Co EV-to-Revenue Chart

Gan & Lee Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.02 9.58 8.13 10.14 7.92

Gan & Lee Pharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.25 8.53 8.23 7.92 7.13

Competitive Comparison of Gan & Lee Pharmaceuticals Co's EV-to-Revenue

For the Medical Instruments & Supplies subindustry, Gan & Lee Pharmaceuticals Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gan & Lee Pharmaceuticals Co's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gan & Lee Pharmaceuticals Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gan & Lee Pharmaceuticals Co's EV-to-Revenue falls into.


;
;

Gan & Lee Pharmaceuticals Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Gan & Lee Pharmaceuticals Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=32162.077/3469.881
=9.27

Gan & Lee Pharmaceuticals Co's current Enterprise Value is ¥32,162 Mil.
Gan & Lee Pharmaceuticals Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,470 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gan & Lee Pharmaceuticals Co  (SHSE:603087) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Gan & Lee Pharmaceuticals Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=57.16/5.892
=9.70

Gan & Lee Pharmaceuticals Co's share price for today is ¥57.16.
Gan & Lee Pharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥5.89.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gan & Lee Pharmaceuticals Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gan & Lee Pharmaceuticals Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Gan & Lee Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 8, 1st Nanfeng West Road, Zhenxian Town, Tongzhou District, Beijing, CHN, 101102
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
Executives
Gan Zhong Ru Director

Gan & Lee Pharmaceuticals Co Headlines

No Headlines